PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

This phase I trial studies the side effects of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in treating patients with ovarian, uterine, appendiceal, stomach (gastric), or colorectal cancer that has spread to the lining of the abdominal cavity (peritoneal carcinomatosis). Chemotherapy drugs, such as cisplatin, doxorubicin, oxaliplatin, leucovorin, fluorouracil, mitomycin, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. PIPAC is a minimally invasive procedure tha

Trial Details

NCT ID
NCT04329494
Phase
PHASE1
Sponsor
City of Hope Medical Center
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Biopsy
  • Cisplatin
  • Doxorubicin
  • Fluorouracil
  • Intraperitoneal Chemotherapy
  • Irinotecan
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Greenlawn, New York, United States|40.86899,-73.36512

Key Eligibility Criteria

  • Documented informed consent of the participant and/or legally authorized representative
  • Patients must have histologically confirmed ovarian, uterine, gastric, appendiceal or colorectal cancer with PC
  • Prior IP chemotherapy is permitted
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) =\< 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →